Triple
T5960345
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Eisai and Biogen |
E132619
|
entity |
| Predicate | developed |
P73
|
FINISHED |
| Object | aducanumab |
E24938
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: aducanumab | Statement: [Eisai and Biogen, developed, aducanumab]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: aducanumab Context triple: [Eisai and Biogen, developed, aducanumab]
-
A.
Aduhelm
chosen
Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
-
B.
ocrelizumab
Ocrelizumab is a humanized monoclonal antibody used as a disease-modifying therapy for multiple sclerosis, particularly targeting CD20-positive B cells to reduce disease activity.
-
C.
ansuvimab
Ansuvimab is a monoclonal antibody used as a therapeutic treatment for infection caused by Zaire ebolavirus (Ebola virus).
-
D.
Donepezil
Donepezil is a cholinesterase inhibitor medication primarily used to treat cognitive symptoms of Alzheimer's disease.
-
E.
faricimab
Faricimab is a bispecific monoclonal antibody used to treat neovascular eye diseases such as wet age-related macular degeneration and diabetic macular edema by targeting both VEGF-A and Ang-2 pathways.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c0086c2364819091e9fe2f58fa2517 |
completed | March 22, 2026, 3:19 p.m. |
| NER | Named-entity recognition | batch_69c039fd6dd48190a6020bef38b1be82 |
completed | March 22, 2026, 6:50 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c0e3e8f234819099336503a797e55b |
completed | March 23, 2026, 6:55 a.m. |
Created at: March 22, 2026, 4:02 p.m.